Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Language English Country England, Great Britain Media print-electronic
Document type Clinical Trial, Phase IV, Journal Article
PubMed
31084373
DOI
10.2217/fon-2018-0934
Knihovny.cz E-resources
- Keywords
- VEGF, biomarkers, efficacy, pancreatic neuroendocrine tumor, sunitinib,
- MeSH
- Progression-Free Survival MeSH
- Pharmacogenomic Testing MeSH
- Protein Kinase Inhibitors administration & dosage adverse effects MeSH
- Interleukin-1beta genetics MeSH
- Polymorphism, Single Nucleotide MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Pancreatic Neoplasms drug therapy genetics mortality MeSH
- Neuroendocrine Tumors drug therapy genetics mortality MeSH
- Aged MeSH
- Sunitinib administration & dosage adverse effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase IV MeSH
- Names of Substances
- IL1B protein, human MeSH Browser
- Protein Kinase Inhibitors MeSH
- Interleukin-1beta MeSH
- Sunitinib MeSH
Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
Boston University and Boston Medical Center Boston MA USA
Centrul de Oncologie Sf Nectarie Oncologie Medicala Craiova Romania
Department of Gastroenterology Oslo University Hospital Rikshospitalet Oslo Norway
Department of Medical Oncology Fundeni Clinical Institute Bucharest Romania
Department of Medical Oncology Paris Saint Joseph Hospital Group Paris France
Faculty of Medicine Masaryk Memorial Cancer Institute Masaryk University Brno Czech Republic
References provided by Crossref.org
